YOLFTbeta
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd

Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd

301126 · SHE · Healthcare / Pharmaceutical Retailers

8.80CNY-0.22 (-2.44%)

Price History

Full chart

Market Stats

Previous Close9.02
Open8.91
Day Range8.76 – 9.08
52-Week Range7.65 – 14.82
Volume2.72M
Market Cap2.16B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.14
Dividend Yield0.99%
Beta0.63
50-Day Avg9.90
200-Day Avg11.08

About

Tat Ka Wai Hong Pharmaceutical Industry Group Co., Ltd. engages in pharmaceutical manufacturing, distribution, retail, and research and development activities in China and Hong Kong. The company operates retail pharmacy services, including Direct-to-Patient specialty pharmacy operations covering medications for cancer treatment, antiviral therapies, and organ transplant procedures. It also serves as an emergency pharmaceutical storage provider and public health emergency supply contractor for Hunan Province. Additionally, the company provides pharmaceutical services, including patient health record management, chronic disease management, and a patient data management system. It manufactures pharmaceutical products. The company also operates a pharmaceutical wholesaling and distribution business across Hunan Province. Additionally, it operates a full-time specialized medical institution, conducts pharmaceutical research and development activities, and engages in regenerative medicine operations. The company offers Chinese patent medicines, chemical pharmaceuticals, medical devices, cleansing and care products, medicinal wines, and food products. It serves hospitals, medical institutions, institutional pharmacy clients, and individual patients. TAT KA WAI HONG Pharmaceutical Industry Group Co., Ltd. was formerly known as Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. and changed its name to Tat Ka Wai Hong Pharmaceutical Industry Group Co., Ltd. in September 2026. Tat Ka Wai Hong Pharmaceutical Industry Group Co., Ltd. was founded in 2002 and is based in Changsha, China.

Company Details

  • SectorHealthcare
  • IndustryPharmaceutical Retailers
  • CEOMs. Shengli Hu
  • Employees5.34K
  • HeadquartersNo.30, Fuling Road, Changsha, China, 410000, China
  • Websitehttps://djwk.com.cn

Leadership

  • Ms. Shengli HuGM, Financial Director & Director · b. 1974
  • Ms. Shanhu ChenDirector & Deputy GM · b. 1983
  • Ms. Qian JiangBoard Secretary & Director · b. 1988
  • Hao QinAccounting Supervisor

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.46B2.34B2.59B3.29B3.90B5.23B5.14B
Growth (%)--4.75%+10.79%+27.01%+18.56%+34.07%-1.70%
Cost of Revenue2.17B2.07B2.29B2.90B3.33B4.19B4.21B
Gross Profit290.16M268.90M305.56M396.06M576.87M1.04B936.34M
Gross Margin11.81%11.49%11.79%12.03%14.78%19.88%18.20%
Operating Expense119.27M140.45M159.74M262.54M432.49M830.81M826.82M
Operating Income170.89M128.45M145.81M133.53M144.37M209.39M109.52M
Operating Margin6.96%5.49%5.63%4.06%3.70%4.00%2.13%
EBITDA373.98M213.74M152.17M155.90M195.09M321.42M42.83M
EBITDA Margin15.22%9.13%5.87%4.74%5.00%6.14%0.83%
Net Income87.65M64.85M68.26M51.08M34.30M26.57M-242.46M
Net Income Margin3.57%2.77%2.63%1.55%0.88%0.51%-4.71%
R&D---524.03K7.17M16.26M11.85M
R&D as % of Total Revenue---0.02%0.18%0.31%0.23%
Interest Expense201.17M31.55M33.48M37.45M63.10M98.60M106.76M
Interest Expense % of Total Revenue8.19%1.35%1.29%1.14%1.62%1.88%2.08%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.02B2.20B2.99B3.93B5.28B6.18B6.34B
Total Liabilities1.04B1.16B1.32B2.11B3.50B4.33B4.74B
Total Equity977.24M1.04B1.68B1.72B1.75B1.76B1.49B
Cash162.07M228.98M748.07M543.00M649.40M619.85M586.73M
Net Debt264.41M442.67M-866.57M1.71B2.15B2.44B

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow135.91M-151.46M-161.81M-493.96M27.13M24.04M-149.12M
Capital Expenditure32.50M45.95M33.29M208.73M226.70M187.14M104.63M
Free Cash Flow103.41M-197.41M-195.10M-702.69M-199.57M-163.10M-253.75M
Dividends Paid37.63M30.97M30.97M41.22M72.45M92.35M111.99M
FCF to OCF76.09%130.33%120.57%142.26%-735.59%-678.41%170.17%
Dividend Paid to FCF36.39%-15.69%-15.87%-5.87%-36.30%-56.62%-44.13%

Earnings

Report DateDec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------
EPS Actual0.090.090.090.07-0.010.070.010.030.050.090.060.02-0.050.02-0.010.02-1.210.030.01
Surprise-------------------
Timing-------------------

Key Statistics & Ratios

Market Cap2.16B
Enterprise Value5.10B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.42
Price / Book1.42
EPS-1.14
Book Value7.28
Revenue (TTM)5.14B
Gross Profit (TTM)979.32M
EBITDA173.41M
Profit Margin-4.60%
Operating Margin3.91%
Return on Equity-12.71%
Return on Assets0.99%
Shares Outstanding205.40M
Shares Float107.76M
Beta0.63
Dividend Yield0.99%
Dividend Rate0.10
Payout Ratio66.67%

Dividends

20252×
0.02Dec 15, 20250.08Jul 7, 2025
20241×
0.04May 29, 2024
20231×
0.03Jun 12, 2023
20221×
0.03Jun 21, 2022